YOLFTbeta
Zhejiang Starry Pharm Co Ltd

Zhejiang Starry Pharm Co Ltd

603520 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

7.75CNY-0.22 (-2.76%)

Price History

Full chart

Market Stats

Previous Close7.97
Open7.96
Day Range7.72 – 7.98
52-Week Range7.89 – 14.37
Volume8.07M
Market Cap3.84B
P/E (TTM)218.75
Forward P/E0.00
EPS0.04
Dividend Yield3.43%
Beta0.42
50-Day Avg8.72
200-Day Avg10.01

About

Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iodine-methyl, iodophorol, ioflufenicol, iopromide gadoxime meglumine, gadolinate dimeglumine, gadolinium, and iohexol injections; contrast agent APIs and intermediates consisting of iohexol, iopamidol, iodixanol, iodimeperidine, iopromide, iodophorol, iodophorol hydrolysate, iohexol hydrolysate, gadobacterium meglumine iodide, and triiodoisophthaloyl chloride esters; levofloxacin hydrochloride, levofloxacin, levofluorocycloester, and levofluorocarboxylic acid; and CMO and CDMO series, including loxoprofen sodium, loxoprofen acid, trimethyliodosilane, 2-iodo-5-methylbenzoic acid, methyl o-iodobenzoate, and iodobenzene. It also engages in technology promotion and application; investment; physical education; and wholesale activities. Zhejiang Starry Pharmaceutical Co.,Ltd. was incorporated in 1997 and is headquartered in Taizhou, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Weiyi Shen
  • Employees1.91K
  • HeadquartersModern Industrial Cluster Area, Taizhou, China, 317306, China
  • Websitehttps://www.starrypharm.com

Leadership

  • Mr. Weiyi ShenVice Chairman & GM · b. 1980
  • Mr. Junfeng GuoSecretary & CFO · b. 1985
  • Mr. Chun YeDeputy General Manager · b. 1979
  • Mr. Zhijun YangDeputy General Manager · b. 1981
  • Wentao HuangAccounting Supervisor

Financials

Income Statement

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue506.58M574.71M685.90M658.48M695.66M672.95M710.94M890.47M1.31B1.37B2.00B2.13B2.20B2.35B2.45B
Growth (%)-+13.45%+19.35%-4.00%+5.65%-3.27%+5.65%+25.25%+46.98%+4.45%+46.29%+6.57%+3.04%+7.02%+4.07%
Cost of Revenue345.20M432.63M503.79M451.02M437.35M416.80M444.70M531.63M751.11M767.30M1.26B1.63B1.69B1.92B1.94B
Gross Profit161.38M142.08M182.11M207.47M258.31M256.15M266.24M358.84M557.74M599.79M744.81M502.59M507.69M430.39M503.59M
Gross Margin31.86%24.72%26.55%31.51%37.13%38.06%37.45%40.30%42.61%43.87%37.24%23.58%23.12%18.31%20.59%
Operating Expense84.14M77.91M84.64M132.45M164.63M162.69M159.37M232.01M327.42M305.86M345.04M558.38M458.50M483.90M366.54M
Operating Income77.24M64.17M97.47M75.02M93.68M93.45M106.87M126.83M230.32M293.94M399.77M-55.79M49.19M-53.51M137.06M
Operating Margin15.25%11.17%14.21%11.39%13.47%13.89%15.03%14.24%17.60%21.50%19.99%-2.62%2.24%-2.28%5.60%
EBITDA115.62M104.06M146.14M164.27M189.37M189.05M211.86M269.67M416.95M523.69M624.88M189.93M333.56M264.23M326.64M
EBITDA Margin22.82%18.11%21.31%24.95%27.22%28.09%29.80%30.28%31.86%38.31%31.25%8.91%15.19%11.24%13.36%
Net Income67.57M35.78M63.66M67.70M68.94M76.12M83.12M93.68M170.33M238.73M323.75M-75.85M44.23M-49.10M10.23M
Net Income Margin13.34%6.23%9.28%10.28%9.91%11.31%11.69%10.52%13.01%17.46%16.19%-3.56%2.01%-2.09%0.42%
R&D25.92M27.86M31.36M31.52M40.39M49.06M53.13M66.13M77.78M87.84M124.58M132.61M134.56M140.67M128.22M
R&D as % of Total Revenue5.12%4.85%4.57%4.79%5.81%7.29%7.47%7.43%5.94%6.43%6.23%6.22%6.13%5.99%5.24%
Interest Expense13.55M26.12M28.80M33.48M38.22M26.24M36.02M66.28M86.08M93.76M76.05M96.50M108.65M102.52M79.13M
Interest Expense % of Total Revenue2.68%4.55%4.20%5.08%5.49%3.90%5.07%7.44%6.58%6.86%3.80%4.53%4.95%4.36%3.24%

Balance Sheet

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets724.08M825.38M1.01B1.15B1.48B1.89B2.01B3.07B3.48B4.41B4.90B5.30B5.52B6.05B6.16B
Total Liabilities422.27M488.57M622.78M718.34M1.02B1.07B1.14B2.14B2.46B2.54B2.68B3.53B3.76B3.41B3.59B
Total Equity294.44M330.23M380.39M421.09M440.53M810.07M857.18M891.04M995.80M1.82B2.17B1.77B1.75B2.63B2.56B
Cash48.45M49.26M53.63M49.07M126.49M162.94M197.63M187.12M433.79M799.49M775.74M661.56M565.13M603.35M415.34M
Total Debt292.72M352.57M497.02M569.02M874.18M925.70M1.02B1.85B2.08B2.08B1.91B2.78B2.59B1.98B-
Net Debt244.28M303.31M443.39M519.96M747.69M762.76M827.34M1.66B1.65B1.28B1.13B2.12B2.02B1.37B2.16B

Cash Flow

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-41.07M103.34M74.99M144.00M94.88M7.68M18.10M191.84M246.77M174.48M508.84M-78.37M46.13M193.50M3.67M
Investing Cash Flow-110.30M-124.98M-184.20M-160.72M-240.64M-264.56M17.40M-931.57M-132.15M-311.76M-282.28M-332.22M-255.56M-490.74M-
Financing Cash Flow137.23M36.87M102.75M14.08M161.71M296.07M10.65M704.29M72.52M537.75M-301.79M363.58M83.01M299.03M-
Capital Expenditure130.61M138.28M188.42M206.76M244.66M188.51M90.62M162.40M133.28M153.17M303.88M472.18M266.22M480.62M269.20M
Free Cash Flow-171.68M-34.94M-113.43M-62.76M-149.78M-180.83M-72.51M29.43M113.49M21.31M204.96M-550.56M-221.67M-287.12M-265.53M
Dividends Paid14.15M22.98M41.70M63.93M90.04M84.86M88.62M108.39M35.92M58.68M122.43M122.44M68.25M128.42M145.98M
FCF to OCF417.99%-33.81%-151.25%-43.58%-157.86%-2354.65%-400.51%15.34%45.99%12.22%40.28%702.48%-480.58%-148.38%-7241.56%
Dividend Paid to FCF-8.24%-65.77%-36.76%-101.86%-60.12%-46.93%-122.21%368.28%31.65%275.31%59.74%-22.24%-30.79%-44.73%-54.98%

Earnings

Report DateApr 29, 2016Aug 26, 2016Sep 30, 2016Dec 31, 2016Apr 18, 2017Aug 27, 2017Oct 27, 2017Mar 27, 2018Apr 29, 2018Aug 28, 2018Oct 27, 2018Mar 25, 2019Apr 26, 2019Aug 27, 2019Oct 28, 2019Mar 30, 2020Apr 30, 2020Aug 27, 2020Oct 29, 2020Dec 31, 2020Apr 28, 2021Aug 27, 2021Oct 29, 2021Apr 25, 2022Aug 25, 2022Oct 27, 2022Apr 27, 2023
EPS Estimate---------------------------
EPS Actual0.080.070.050.040.090.080.050.040.070.130.060.030.120.160.130.140.190.230.180.120.260.270.190.30-0.05-0.15-0.24
Surprise---------------------------
TimingPre-marketPre-market--After-hoursAfter-hours---After-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-market--After-hoursPre-marketPre-marketAfter-hoursPre-marketPre-market

Key Statistics & Ratios

Market Cap3.84B
Enterprise Value6.35B
Trailing P/E218.75
Forward P/E0.00
Price / Sales1.56
Price / Book1.53
EPS0.04
Book Value5.65
Revenue (TTM)2.46B
Gross Profit (TTM)468.80M
EBITDA333.81M
Profit Margin0.85%
Operating Margin2.07%
Return on Equity0.81%
Return on Assets0.92%
Shares Outstanding438.41M
Shares Float327.20M
Beta0.42
Dividend Yield3.43%
Dividend Rate0.30
Payout Ratio750.00%

Dividends

20231×
0.20Jun 30, 2023
20221×
0.50Jun 17, 2022
20211×
0.36Jun 24, 2021
20201×
0.25Jun 1, 2020
20191×
0.15Jun 25, 2019
20181×
0.18Jun 28, 2018
20171×
0.11Jun 2, 2017
20161×
0.11Jun 13, 2016

Stock Splits

  • Jun 17, 20227:5
  • Jun 1, 20207:5
  • Jun 25, 20197:5